[Historical aspect of molecular-targeted therapy for cancer].
Recently, discovery and identification of critical molecules responsible for cancer progression lead to development of specific target-directed therapies, including monoclonal antibodies and small molecular compounds. For the past 15 years, the advent of target-specific therapeutics has remarkably improved the clinical outcomes of certain patients with various malignancies, and it was followed by the understanding of mechanism of the drug resistance. Moreover, useful biomarkers were developed to further increase the power of patient selection for molecular-targeted therapy. From the historical point of view, we review the progress in developing new molecular-targeted drugs for personalized medicine.
Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, The University of Tokushima Graduate School.
Saburo
S
Sone
Kenji
K
Otsuka
Makoto
M
Tobiume
Hiroya
H
Tada
D000818:Animals; D015415:Biomarkers; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D058990:Molecular Targeted Therapy / Q000266:history*; D009369:Neoplasms / Q000188:drug therapy* / Q000266:history
D015415:Biomarkers